欧盟疫苗上市后安全监测体系研究

摘要/Abstract

摘要： 目的通过介绍欧盟疫苗上市后安全监测体系,为我国疫苗上市后监管提供参考。方法采用文献分析的方法,围绕疫苗上市后监测体系,搜集有关法律法规文献。结果通过法律框架,欧盟提出了疫苗安全监测的特殊要求,以统一的数据库为基础,采用风险管理系统、定期安全性更新报告、设置重点监测名单等措施识别潜在不良反应信号,并通过注册后安全性研究对疫苗安全进行再评价。结论欧盟建立了统一、长期监测体系和完善的药品安全沟通机制,将风险控制理念贯穿始终,这对我国有一定的借鉴意义。

关键词: 疫苗, 上市后监测体系, 参考

Abstract: Objective To offer reference for China, Post-marketing Surveillance System of Vaccine in European Union was introduced. Methods Literatures, regulations and laws relating to post-marketing surveillance system of vaccine were collected. Results Specific requirements were proposed by European Union through legal framework. Risk management system, periodic safety update report and additional monitoring list were utilized to recognize potential adverse events signal. Reevaluation of vaccine was proceeded by post-authorization safety studies. Conclusion European Union has established unified long-term monitoring system, completed drug safety communication mechanism and put the idea of risk control all through the process of surveillance.

Key words: vaccine, post-marketing surveillance system, reference

中图分类号:

郗昊, 王翀. 欧盟疫苗上市后安全监测体系研究[J]. 中国药物警戒, 2018, 15(12): 713-720.

XI Hao, WANG Chong. Research on Post-marketing Surveillance System of Vaccine in European Union[J]. Chinese Journal of Pharmacovigilance, 2018, 15(12): 713-720.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/

https://zgywjj.magtechjournal.com/CN/Y2018/V15/I12/713

参考文献

[1] Cranfield M R.Vaccination[M]// The International Encyclopedia of Primatology. John Wiley & Sons, Inc. 2017.
[2] EMA. EU Administrative Procedure For Official Control Authority Batch Release [EB/OL].(2017-12-28)[2018-09-13].https://www.edqm.eu/sites/default/files/eu-administrative-procedure-ocabr.zip.
[3] EMA.Medicines under additional monitoring [EB/OL].(2013-04-25)[2018-09-13]. http://www.ema.europa.eu/docs/en_GB/docu-ment_library/Other/2013/04/WC500142430.pdf.
[4] WHO. The Importance of Pharmacovigilance: safety monitoring of medicinal products [EB/OL]. (2002-01)[2018-09-13] http://apps.who.int/medicinedocs/pdf/s4893e/s4893e.pdf.
[5] 刘夏. “反应停”与“海豹胎”药物立法前的阴影[J]. 新知客, 2009(4):99-103.
[6] EMA. "Adaptive licensing" or "adaptive pathways":Deregulation under the guise of earlier access[EB/OL].(2015-10-16)[2018-09-13].https://ec.europa.eu/health/sites/health/files/files/committee/stamp/2015-10_stamp3/3c_prescrire_position_paper.pdf.
[7] EMA. History of EMA [EB/OL].(2015-01-26)[2018-09-13]. http:// www.ema.europa.eu/docs/en_GB/document_library/Other/2015/01/ WC500180533.pdf.
[8] Europe Commission. Directive2001/83/EC of the European Parliament and of the Council [EB/OL].(2001-11-28)[2018-09-13]. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/uri=CELEX:32001L0083&qid=1536934665173&from=EN.
[9] Europe Commission. Regulation (EC) No 726/2004 of the European Parliament and of the Council[EB/OL].(2004-03-31)[2018-09-13].https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1536935152464&uri=CELEX:32004R0726.
[10] Europe Commission. Directive2004/27/EC of the European Parliament and of the Council[EB/OL].(2004-03-31)[2018-09-13]. https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1536935-784753&uri=CELEX:32004L0027.
[11] Europe Commission. Strengthening pharmacovigilance to reduce adverse effects of medicines[EB/OL].(2008-11-10)[2018-09-13]. http://europa.eu/rapid/press-release_MEMO-08-782_en.htm.
[12] Assessment of the Community System of Pharmacovigilance- European Commission Public Consultation-presentation of results[EB/OL].(2007-02)[2018-09-13]. https://ec.europa.eu/health/sites/health/files/files/pharmacovigilance/docs/2007_02_26/analysis_consultation_responses_en.pdf.
[13] Directive Borg J J, Aislaitner G, Pirozynski M, et al. Strengthening and Rationalizing Pharmacovigilance in the EU: Where is Europe Heading to?[J]. Drug Saf, 2011, 34(3):187-197.
[14] EMA. Pharmacovigilance Risk Assessment Committee[EB/OL].(2013-03-03)[2018-09-13]. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2013/03/WC500139609.pdf.
[15] Europe Commission. Regulation (EU) No1027/2012 of the European Parliament and of the Council[EB/OL].(2012-10-25)[2018-09-13]. https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=1536940343557&uri=CELEX:32012R1027.
[16] Europe Commission. Directive2012/26/EU of the European Parliament and of the Council[EB/OL].(2012-10-25)[2018-09-13]. https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=15369404-36186&uri=CELEX:32012L0026.
[17] EMA. Guidelines on good pharmacovigilance practices[EB/OL].(2017-10-12)[2018-09-13]. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2017/10/WC500236404.pdf.
[18] EMA. First Annual Report on EudraVigilance for the European Parliament, the Council and the Commission[EB/OL].(2013-03-21)[2018-09-13]. http://www.ema.europa.eu/docs/en_GB/document_library/Report/2013/07/WC500146607.pdf.
[19] Europe Commission. Directive2010/84/EU of the European Parliament and of the Council [EB/OL].(2010-12-31)[2018-09-13]. https://eur-lex.europa.eu/eli/dir/2010/84/oj.
[20] Europe Commission. Regulation (EU) No1235/2010 of the European Parliament and of the Council[EB/OL].(2010-12-31)[2018-09-13]. https://eur-lex.europa.eu/legal-content/EN/TXT/?qid=15396-73802636&uri=CELEX:32010R1235.
[21] EMA. Guideline on good pharmacovigilance practices (GVP) Module I - Pharmacovigilance systems and their quality systems [EB/OL].(2012-06-22)[2018-09-13]https://www.ema.europa.eu/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-i-pharmacovigilance-systems-their-quality-systems_en.pdf.
[22] EMA. Guideline on good pharmacovigilance practices (GVP) Module V-Risk management systems [EB/OL].(2012-07-02)[2018-09-13]https://www.ema.europa.eu/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-v-risk-management-systems-rev-2_en.pdf.
[23] EMA. Guideline on good pharmacovigilance practices (GVP) Module VI-Collection, management and submission of reports of suspected adverse reactions to medicinal products [EB/OL].(2012-07-02)[2018-09-13]https://www.ema.europa.eu/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf.
[24] EMA. Guideline on good pharmacovigilance practices (GVP) Module VI Addendum I - Duplicate management of suspected adverse reaction reports [EB/OL].(2012-07-28)[2018-09-20]https://www.ema.europa.eu/documents/regulatory-procedural-guideline/guideline-good-pharmacovigilance-practices-gvp-module-vi-addendum-i-duplicate-management-suspected_en.pdf.
[25] EMA. Guideline on good pharmacovigilance practices (GVP) Module VII - Periodic safety update report (Rev 1) [EB/OL].(2013-12-09)[2018-09-20]https://www.ema.europa.eu/documents/scientific-
guideline/guideline-good-pharmacovigilance-practices-gvp-module-vii-periodic-safety-update-report_en.pdf.
[26] EMA. Guideline on good pharmacovigilance practices (GVP) Module IX-Signal management (Rev 1) [EB/OL].(2017-10-09)[2018-09-20]https://www.ema.europa.eu/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-ix-signal-management-rev-1_en.pdf.
[27] EMA. Guideline on good pharmacovigilance practices (GVP) Module X - Additional monitoring[EB/OL].(2013-04-19)[2018-09-20]https://www.ema.europa.eu/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-module-x-additional-monitoring_en.pdf.
[28] EMA. List of medicinal products under additional monitoring[EB/OL].(2018-07-25)[2018-09-20]https://www.ema.europa.eu/documents/additional-monitoring/list-medicinal-products-under-additional-monitoring_en-0.pdf.
[29] OU and WP4 Risk Working Group. D4.2 Report on Appraisal of Vaccine Safety Methods [EB/OL].(2014-10-24)[2018-10-06] http://www.advance-vaccines.eu/app/archivos/publicacion/67/ADVAN-CE_D4%202_appraisal%20safety%20methods_final_PU.pdf.
[30] EMA. Model for ENCePP[EB/OL].(2007-05-30)[2018-10-06] http://www.encepp.eu/publications/documents/ENCePPConceptPaper_May07.pdf.
[31] EMA. Guideline on good pharmacovigilance practices (GVP) Product- or Population-Specific Considerations I: Vaccines for prophylaxis against infectious diseases[EB/OL].(2013-12-09)[2018-10-06]https://www.ema.europa.eu/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-product-population-specific-considerations-i-vaccines_en.pdf.
[32] EMA. First Annual Report on EudraVigilance for the European Parliament, the Council and the Commission [EB/OL].(2013-03-21)[2018-10-06] https://www.ema.europa.eu/documents/report/first-annual-report-eudravigilance-european-parliament-council-commission_en.pdf.
[33] EMA.2013 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission [EB/OL].(2014-04-04)[2018-10-06] https://www.ema.europa.eu/documents/report/2013-annual-report-eudravigilance-european-parliament-council-commission_en.pdf.
[34] EMA.2014 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission[EB/OL].(2015-02-27)[2018-10-06] https://www.ema.europa.eu/documents/report/2014-annual-report-eudravigilance-european-parliament-council-commission_en.pdf.
[35] EMA.2015 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission[EB/OL].(2016-03-17)[2018-10-06] https://www.ema.europa.eu/documents/report/2015-annual-report-eudravigilance-european-parliament-council-commission_en.pdf.
[36] EMA.2016 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission[EB/OL].(2017-03-16)[2018-10-06] https://www.ema.europa.eu/documents/report/2016-annual-report-eudravigilance-european-parliament-council-commission_en.pdf.
[37] EMA.2017 Annual Report on EudraVigilance for the European Parliament, the Council and the Commission[EB/OL].(2018-03-15)[2018-10-06] https://www.ema.europa.eu/documents/report/2017-annual-report-eudravigilance-european-parliament-council-commission-reporting-period-1-january_en.pdf.
[38] 张桂菊, 张桂菊, 初晓艺, 等. 欧盟药物警戒体系对我国的启示[J]. 中国药物警戒, 2015, 12(10):593-596.
[39] 董铎, 吴桂枝, 程刚. 欧盟新法规下的药物警戒制度简介[J]. 中国药物警戒, 2012, 9(11):662-665.
[40] EMA. EudraVigilance Operational Plan Milestones2018 to 2020 [EB/OL].(2018-06-08)[2018-10-06].https://www.ema.europa.eu/documents/other/eudravigilance-operational-plan-milestones-2018-2020_en.pdf.
[41] 武楠, 杨悦. 欧盟药物警戒数据库建设对我国的启示[J]. 中国药物警戒, 2018,15(4)230-233.